Oncology

Latest News

Insurance gaps | Image Credit: iQoncept-stock.adobe.com
Insurance Gaps Threaten Cancer Treatment Success

July 7th 2025

Access to and affordability of immune checkpoint inhibitors, which can be lifesaving if patients receive them on time and under optimal circumstances, continue to top the list of reasons behind outcomes disparities for patients who have private insurance vs those who remain uninsured.

Analyzed by birth cohort, the authors found each successive birth cohort had a 7.7% decline in SCLC rates. | Image credit: shidlovski
Decline in SCLC Incidence Expected to Accelerate Through 2050

June 29th 2025

While elevated NLR previously served as a marker of aggressive disease and poor prognosis in SCLC, its prognostic relevance appears to diminish in the context of immunotherapy-based treatment regimens. | Image credit: Crystal light - stock.adobe.com
Challenging the Prognostic Role of NLR in SCLC in the Era of Immunotherapy

June 27th 2025

Gender rights | Image Credit: © Nadzeya-stock.adobe.com
Culture Key to Data Collection of Sexual Orientation and Gender Identity in Cancer Care

June 23rd 2025

AJMC Q&A with Coral Omene, MD, PhD | Background image credit: ipopba - stock.adobe.com
Addressing Cancer Care Challenges for Patients, and Ensuring Equity: Coral Omene, MD, PhD

June 22nd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations
Continuing Medical Education
View All
July 8th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
July 8th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

The Advent of Managed Care
September 26th 2018

The Advent of Managed Care

History of Mergers and Acquisitions in the Healthcare Industry
September 26th 2018

History of Mergers and Acquisitions in the Healthcare Industry

Review Finds Mixed Results for APMs and New Care Delivery Models in Cancer
September 23rd 2018

Review Finds Mixed Results for APMs and New Care Delivery Models in Cancer

Laura Joszt, MA
With cancer costs rising and patients with cancer disproportionately facing financial toxicity, alternative payment and care delivery models are thought to help alleviate some of the cost burden. However, a review finds limited evidence available to evaluate the efficacy of alternative payment and care models in cancer care.
Podcast: This Week in Managed Care—Banning Gag Clauses and Other Health News
September 22nd 2018

Podcast: This Week in Managed Care—Banning Gag Clauses and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
Bidens Celebrate Progress, Highlight Need for More at Biden Cancer Summit
September 22nd 2018

Bidens Celebrate Progress, Highlight Need for More at Biden Cancer Summit

Jaime Rosenberg
The flagship event of more than 450 Biden Cancer Community Summits convening throughout the day is focusing on sharing experiences, promoting new solutions, and bridging gaps in cancer care.
More Data Necessary to Determine Best Treatment Option in Basal Cell Carcinoma
September 21st 2018

More Data Necessary to Determine Best Treatment Option in Basal Cell Carcinoma

Samantha DiGrande
Although many different treatments exist for basal cell carcinoma (BCC), many methods have not been compared in head-to-head randomized trials. A review recently published in Annals of Internal Medicine looked to evaluate the comparative effectiveness and safety of treatments in adults with BCC.
This Week in Managed Care: September 21, 2018
September 21st 2018

This Week in Managed Care: September 21, 2018

This week, the top managed care news included the Senate overwhelmingly voting to ban pharmacist gag clauses; a study found the current vaccine pipeline for HIV, tuberculosis, and malaria may fall short; an expert noted a trend of healthcare cost data seeping into nonhealthcare companies’ earnings calls.
Amgen's AMG 420 Finds Early Success in Patients With Relapsing/Refractory Multiple Myeloma
September 20th 2018

Amgen's AMG 420 Finds Early Success in Patients With Relapsing/Refractory Multiple Myeloma

David Bai
Amgen’s pipeline drug AMG 420, a bispecific T-cell engager (BiTE) for the treatment of patients with relapsing/refractory multiple myeloma (RRMM), has found positive preliminary results in a phase 1 trial.
Dr Denalee O'Malley Highlights Gaps in Cancer Treatment Communication
September 19th 2018

Dr Denalee O'Malley Highlights Gaps in Cancer Treatment Communication

Assessing a patient’s understanding of his or her own illness is important as cancer treatments become more and more complex, said Denalee O’Malley, PhD, LSW, instructor, Department of Family Medicine and Community Health, Rutgers Robert Wood Johnson Medical School.
A Multidisciplinary Approach to Managing Complexities in Cancer Care
September 19th 2018

A Multidisciplinary Approach to Managing Complexities in Cancer Care

As September marks National Ovarian Cancer Awareness Month, we sat down with ovarian cancer survivor Marion Roth and Vaagn Andikyan, MD, gynecologic oncologist, Western Connecticut Health Network, to discuss Marion's cancer journey and the importance of a multidisciplinary care team in treating complexities in cancer care.
Prostate Cancer in Older Men Costs Medicare $1.2 Billion Over 3-Year Period
September 19th 2018

Prostate Cancer in Older Men Costs Medicare $1.2 Billion Over 3-Year Period

Jaime Rosenberg
With general consensus that those 70 years and older should not be routinely screened for prostate cancer, researchers argue that their study results identify an area for cutting low-value services to reduce healthcare spending.
Keytruda Earns Priority Review as Monotherapy in NSCLC
September 17th 2018

Keytruda Earns Priority Review as Monotherapy in NSCLC

Samantha DiGrande
Last week, the FDA granted priority review to a new supplemental Biologics License Application for pembrolizumab (Keytruda) as a monotherapy for first-line treatment of locally advanced or metastatic nonsquamous or squamous non–small cell lung cancer (NSCLC) in patients whose tumors express PD-L1 without EGFR or ALK mutations.
Site Logo
September 17th 2018

Low-Dose Aspirin Won't Prolong Life in Healthy Older People, Study Announces

Mary Caffrey
The study by the National Institute on Aging produced a few surprises and was stopped early when aspirin showed no benefit.
NCCN Working Group Policy Recommendations Address Changing Paradigms in Cancer Care
September 16th 2018

NCCN Working Group Policy Recommendations Address Changing Paradigms in Cancer Care

Jaime Rosenberg
A National Comprehensive Cancer Network (NCCN) working group dedicated to analyzing current challenges under existing policy and treatment paradigms presented their findings and recommendations at an NCCN Policy Summit in Washington, DC.
Delivering High-Quality Care Under Value-Based Payment Models: Where Are We Now?
September 15th 2018

Delivering High-Quality Care Under Value-Based Payment Models: Where Are We Now?

Jaime Rosenberg
As the term “value” has become a norm in healthcare, specifically in oncology, panelists at a National Comprehensive Cancer Network policy summit offered perspectives on where we are now in delivering high-quality cancer care under value-based payment models.
Podcast: This Week in Managed Care—Pushback on Proposed Payment Rules and Other Health News
September 15th 2018

Podcast: This Week in Managed Care—Pushback on Proposed Payment Rules and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
NCCN Report on CAR T-Cell Therapy, Recommendations for Future Use
September 14th 2018

NCCN Report on CAR T-Cell Therapy, Recommendations for Future Use

Samantha DiGrande
A recent report from the National Comprehensive Cancer Network (NCCN) investigated the current state of chimeric antigen receptor (CAR) T-cell therapy and future strategies to consider as the novel immunotherapy evolves and is used in the treatment of more patients.
This Week in Managed Care: September 14, 2018
September 14th 2018

This Week in Managed Care: September 14, 2018

This week, the top managed care news included medical groups asking CMS to halt or slow down its plans to cut physician reimbursement for evaluation and management services; the Senate weighs a package of bills to combat the opioid epidemic; new research shows the Affordable Care Act pushed the uninsured rate down to 10%.
Dr Don Dizon Highlights Services Insurance Should Cover for Women Who Had Breast Cancer
September 14th 2018

Dr Don Dizon Highlights Services Insurance Should Cover for Women Who Had Breast Cancer

There are medications, procedures, and techniques that insurers could do a better job covering that would improve quality for women after breast cancer, said Don S. Dizon, MD, FACP, FASCO, director of Women's Cancers at the Lifespan Cancer Institute, director of medical oncology at Rhode Island Hospital, and associate professor of medicine at The Warren Alpert Medical School of Brown University.
Preventing Transportation of Mutant Protein Can Inhibit Growth of Leukemic Cells
September 13th 2018

Preventing Transportation of Mutant Protein Can Inhibit Growth of Leukemic Cells

Laura Joszt, MA
Researchers at Baylor College of Medicine have found that preventing a mutated protein from leaving the nucleus and traveling to the cytoplasm of the cell can help inhibit the growth of leukemic cells in acute myeloid leukemia.
Cautious Optimism: OCM Participants Seem to Have Improved in Performance Period 2
September 13th 2018

Cautious Optimism: OCM Participants Seem to Have Improved in Performance Period 2

Laura Joszt, MA
An early review of the second performance period of the Oncology Care Model (OCM) seems to show improvements over the first period.
Site Logo
September 13th 2018

Study Discerns Rare Risks of Fatal Side Effects From Cancer Immunotherapy

Allison Inserro
Researchers determined the incidence and timing of rare, fatal side effects from immune checkpoint inhibitors, and said the number is still extremely low.
EU Approves Keytruda for First-Line Treatment of Metastatic Nonsquamous NSCLC
September 12th 2018

EU Approves Keytruda for First-Line Treatment of Metastatic Nonsquamous NSCLC

Samantha DiGrande
Pembrolizumab (Keytruda) earned European approval this week, in combination with platinum-based pemetrexed, for the first-line treatment of metastatic nonsquamous non-small cell lung cancer (NSCLC) in adults whose tumors lack EGFR or ALK mutations.
Site Logo
September 11th 2018

OneOncology Launches to Enable Better Cancer Care in Communities Across America

Three leading oncology practices unite with partners in technology and finance to announce the launch of OneOncology, a patient-centric, physician-driven, and technology-powered company with a mission to improve the lives of everyone living with cancer.
Prescription Drug Coverage Improved Survival for Patients With MM
September 9th 2018

Prescription Drug Coverage Improved Survival for Patients With MM

Laura Joszt, MA
Patients with multiple myeloma (MM) who are enrolled in a Medicare Part D plan or other creditable prescription drug coverage have better survival than patients without prescription drug coverage. According to a study in Journal of Clinical Oncology, this improved survival seemed to be a result of patients having access to all treatment options.
HIV/AIDS Research Has Positive Impacts Across Other Medical Fields
September 6th 2018

HIV/AIDS Research Has Positive Impacts Across Other Medical Fields

Jaime Rosenberg
In addition to the advances made in the HIV space, such as antiretroviral therapies and pre-exposure prophylaxis, the years of research has translated into advances outside the HIV field, including in oncology and other immune diseases.
Bringing Virtual Tumor Boards, Real-Time Data to the Point of Care
September 5th 2018

Bringing Virtual Tumor Boards, Real-Time Data to the Point of Care

As the oncology landscape continues to rapidly evolve, access to real-time data has become increaisngly important, and technology-based medical startups have made their way to the front of the lines with point-of-care tools that use technology to transform cancer care.
Amgen Seeks Expanded Indication for Once-Weekly Kyprolis for Multiple Myeloma
September 4th 2018

Amgen Seeks Expanded Indication for Once-Weekly Kyprolis for Multiple Myeloma

Laura Joszt, MA
Amgen has submitted a supplemental New Drug Application to the FDA to expand the prescribing information of carfilzomib (Kyprolis) to include a once-weekly dosing option in combination with dexamethasone for patients with relapsed or refractory multiple myeloma.
Lay Health Workers May Provide Value for Patients With Cancer in New Payment Models
September 2nd 2018

Lay Health Workers May Provide Value for Patients With Cancer in New Payment Models

Laura Joszt, MA
As the healthcare system considers alternative payment models that reward high-value care delivery, programs that utilize lay health workers (LHW) may be valuable. A study in JAMA Oncology analyzed whether an LHW program can increase the documentation of patients’ care preferences.
What We're Reading: Calif. Drug Price Lawsuit Tossed; Testing ARBs for Cancer Link; Hope for Nonaddictive Painkiller
August 31st 2018

What We're Reading: Calif. Drug Price Lawsuit Tossed; Testing ARBs for Cancer Link; Hope for Nonaddictive Painkiller

AJMC Staff
A judge tossed a lawsuit brought by pharmaceutical companies to block a California law requiring advance notice of big price increases; the FDA is testing all angiotensin II receptor blockers (ARBs) over a discovered impurity that is linked to cancer; research in monkeys has suggested that an experimental painkiller is effective at easing pain without being addictive.
<1
...
394041424344454647
...
186>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo